Most Read Articles
4 months ago
Erectile dysfunction may potentially be associated with gout, a new systematic report and meta-analysis reveals. However, the low quality and high degree of heterogeneity among the studies included reduce the certainty of this conclusion.
6 days ago
Patients with juvenile-onset systemic lupus erythematosus (jSLE) have a higher frequency of renal involvement, cutaneous symptoms, oral ulcers, neuropsychiatric (NP) manifestations, autoimmune hemolytic anaemia (AIHA) and anti-dsDNA positivity than those with adult-onset SLE (aSLE), a recent study has found.
one month ago
At the International Osteoporosis Foundation Regionals – 6th Asia-Pacific Osteoporosis Meeting in Singapore, Professor Olivier Bruyère shared about the algorithm for the management of knee OA by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). MIMS Doctor also spoke to Professor Jean-Yves Reginster, president of ESCEO about this algorithm and the role of SYSADOAs in the control of pain and prevention of disease progression.
one month ago
The goal of this module is to provide an overview on ankylosing spondylitis. Click here to learn more.

Adalimumab plus MTX effective in JIA-associated uveitis

9 days ago

Combination therapy with methotrexate (MTX) and adalimumab, a human anti–tumour necrosis factor α monoclonal antibody, is effective in the treatment of juvenile idiopathic arthritis (JIA)-associated uveitis, according to a recent report.


In the multicentre, double-blind study, researchers assessed the efficacy and safety of adalimumab in children and adolescents ≥2 years of age who had active JIA-associated uveitis and who were receiving a stable dose of MTX. The children were randomized in a 2:1 ratio to receive subcutaneous adalimumab (20 or 40 mg based on body weight) or placebo every 2 weeks until treatment failure or until 18 months had elapsed. They were followed-up for 2 years from the time of randomization. The primary endpoint was time to treatment failure.


The trial was halted early when the prespecified stopping criteria were met after the enrolment of 90 of 114 patients. It was clear that the therapy was effective as the treatment failure rate was 27 percent among adalimumab recipients but 60 percent among those in the placebo group (hazard ratio (HR), 0.25, 95 percent confidence interval (CI) 0.12–0.49; p<0.0001 (this HR was the prespecified stopping boundary). However, the rates of adverse events (10.07 events/patient-year vs 6.51 events/patient-year) and serious adverse events (0.29 events/patient-year vs 0.19 events/patient-year) were also higher among adalimumab recipients. 

Editor's Recommendations
Most Read Articles
4 months ago
Erectile dysfunction may potentially be associated with gout, a new systematic report and meta-analysis reveals. However, the low quality and high degree of heterogeneity among the studies included reduce the certainty of this conclusion.
6 days ago
Patients with juvenile-onset systemic lupus erythematosus (jSLE) have a higher frequency of renal involvement, cutaneous symptoms, oral ulcers, neuropsychiatric (NP) manifestations, autoimmune hemolytic anaemia (AIHA) and anti-dsDNA positivity than those with adult-onset SLE (aSLE), a recent study has found.
one month ago
At the International Osteoporosis Foundation Regionals – 6th Asia-Pacific Osteoporosis Meeting in Singapore, Professor Olivier Bruyère shared about the algorithm for the management of knee OA by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). MIMS Doctor also spoke to Professor Jean-Yves Reginster, president of ESCEO about this algorithm and the role of SYSADOAs in the control of pain and prevention of disease progression.
one month ago
The goal of this module is to provide an overview on ankylosing spondylitis. Click here to learn more.